Whitehawk takes SEZ6-directed ADC into US clinic, with cash guided into 2028
The US biotech's lead lung cancer asset has begun human testing under a regulatory fast lane, while the balance sheet shows $169.7m and a quarterly loss of $21.2m.
Whitehawk Therapeutics has begun a US Phase 1 study of HWK-206, an antibody-drug conjugate (ADC) aimed at the SEZ6 protein. The company disclosed this on 9 November alongside its third-quarter 2026 results. The drug is being developed for small-cell lung cancer and other neuroendocrine tumours.
The US Food and Drug Administration has given HWK-206 Fast Track designation. As general context, the status is reserved for products aimed at serious conditions with unmet need. It brings more frequent contact with the agency and can make a future filing eligible for rolling submission, subject to the agency's criteria. Whitehawk has also submitted an investigational new drug application in China, which points to parallel development in the two markets.
The results summary gives no detail on enrolment, dose levels or timing for the HWK-206 study, so there is nothing yet to judge its clinical ambitions or pace.
On the balance sheet, Whitehawk reported a third-quarter net loss of $21.2m and $169.7m in cash. The company's own announcement says that cash funds operations into the second half of 2028. Its next data are due in the first half of 2027, when it expects first Phase 1 results for two other programmes, HWK-007 and HWK-016.
Why it matters
- Fast Track on a first-in-human ADC gives Whitehawk a closer line to the FDA early, though it does not alter the odds of clinical success.
- A China IND filing alongside the US trial suggests a two-region plan for HWK-206, which partnering and regulatory teams will want to track.
- The company-guided cash runway into 2H 2028 spans the expected 1H 2027 readouts for HWK-007 and HWK-016, the next tests of the pipeline.
Company's press release (SEC filing): Whitehawk Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
